Edwards Lifesciences (EW) Tops Q2 EPS by 1c; offers guidance
Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.70, $0.01 better than the analyst estimate of $0.69. Revenue for the quarter came in at $1.63 billion versus the consensus estimate of $1.65 billion.
GUIDANCE
The company expects Q3 sales of $1.56 to $1.64 billion, versus the consensus of $1.623 billion assuming Critical Care is included for the entire third quarter. The company expects EPS in Q3 of $0.67 to $0.71, versus the consensus of $0.69 assuming the inclusion of Critical Care and no impact from previously announced acquisitions. The company will provide pro forma information for Q4 2024 when third quarter results are reported, reflecting the sale of Critical Care and the acquisitions announced this month.
For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.